Understanding the pathobiology in patent ductus arteriosus in prematurity—beyond prostaglandins and oxygen

Tim Hundscheid(Radboud University Nijmegen), Willem P. de Boode(Radboud University Nijmegen), Robin van der Lee(Radboud University Nijmegen), Martijn van den Broek(Radboud University Nijmegen)
Pediatric Research
April 9, 2019
10.1038/s41390-019-0387-7
Cited by 46

Related Papers

Clinical review: Update on hemodynamic monitoring - a consensus of 16
|Critical Care|2011|415
Expectant Management or Early Ibuprofen for Patent Ductus Arteriosus
|New England Journal of Medicine|2022|195
Neonatal sepsis: need for consensus definition, collaboration and core outcomes
|Pediatric Research|2020|106
Neonatal sepsis definitions from randomised clinical trials
|Pediatric Research|2021|99
Early treatment versus expectative management of patent ductus arteriosus in preterm infants: a multicentre, randomised, non-inferiority trial in Europe (BeNeDuctus trial)
|BMC Pediatrics|2018|81